CBU
CHRS icon

CIBC Bancorp USA’s Coherus Oncology CHRS Stock Holding History

CIBC Bancorp USA’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$18.5K Buy
+11,306
New +$12.6K ﹤0.01% 1457

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

CIBC Bancorp USA's CHRS Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Coherus Oncology (CHRS) in Q3 2025: 11,306 shares worth $18.5K. The stake represents ﹤0.01% of the portfolio and ranks #1457 among its holdings.

114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • CIBC Bancorp USA held 11,306 shares of Coherus Oncology worth $18.5K as of Q3 2025.
  • Coherus Oncology was a new CIBC Bancorp USA position in Q3 2025.
  • Coherus Oncology made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1457 holding.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.